Author: canwell

CanWell Pharma will present the latest research developments at the 39th of The Society for Immunotherapy of Cancer (SITC) Annual Meeting held on Nov6-10, 2024 in Houston, TX. The research developments are from its two different studies and will be conducted on the following two posters:

Date: Nov8, 2024

Location: Exhibit Halls A B George R. Brown Convention Center

Poster 1 (No. 689)

Results From A Phase I Dose Escalation Trial of CAN1012 in Patients With Solid Tumors

Poster 2 (No. 1345)

CAN2109: Preclinical Development of A Novel Long-Acting Immunogenic Cell Death (ICD) Inducer for Cancer Therapy

CanWell Pharma will present its latest research developments at the 15^th World ADC in San Diego, CA held on Nov 5-7, 2024. The presentation will be conducted on a poster during Poster Session of the conference. The poster covers newest research updates on Dual-Payload ADCs, which may make significant progress in overcoming tumor heterogeneity and drug resistance.

Poster Title: Dual-Payload ADCs for Overcoming Drug Resistance and Tumor Heterogeneity

Date: Nov 5-6, 2024

Location: The Exhibition Hall

Read More (click to read the original article)

CanWell Pharma announced that its First-in-Class innovative drug CAN2109, has been granted IND approval by the China National Medical Products Administration (NMPA).  CanWell plans to immediately initiate the patient enrollment to evaluate CAN2109’s safety, PK, PD and clinical activity for the treatment of various solid tumors.

CAN2109 is a novel long-acting Immunogenic cell death (ICD) inducer, which acts as a bi-functional immune modulator to kill tumor cells while preserving tumor antigens for efficient cross-priming of tumor-specific T cells.  CAN2109 not only possesses direct tumor cell killings, but also induces strong cell-mediated immune responses including both CD4+ and CD8+ T cells activation. In addition, CAN2109 synergizes with checkpoint inhibitors to induce systemic immunity with regression of local and distant tumors.

CanWell Pharma announced that its First-in-Class innovative drug CAN2109, has been granted clinical approval by the US Food and Drug Administration (FDA) and it will soon conduct Phase I clinical trial for various solid tumors.

CAN2109 is a novel long-acting Immunogenic cell death (ICD) inducer, which acts as a bi-functional immune modulator to kill tumor cells while preserving tumor antigens for efficient cross-priming of tumor-specific T cells.  CAN2109 not only possesses direct tumor cell killings, but also induces strong cell-mediated immune responses including both CD4+ and CD8+ T cells activation. In addition, CAN2109 synergizes with checkpoint inhibitors to induce systemic immunity with regression of local and distant tumors.

CanWell announced today that the preclinical research results and clinical plan of the company’s TLR7 agonist CAN1012 would be presented at the 4th STING & TLR Targeted Therapy Summit in 2023.

CAN1012 is a highly selective small-molecule TLR7 agonist developed by CanWell with global intellectual property rights. Preclinical studies have shown that it has high selectivity and potency, with low toxicities. It can exert sustained stimulation of the target cells in the tumor microenvironment, transforming “cold” tumors with low immune response into “hot” tumors with augmented immune response, playing a crucial bridging role in the innate and adaptive immune systems. In addition, it may be administered in combination with various drugs such as immunotherapy checkpoint inhibitors, as well as radiotherapy and chemotherapy, to produce highly synergistic effects.

The CAN1012 Phase I clinical trial is an open-label, multicenter, dose-escalation, and dose-expansion study aimed at evaluating the safety, tolerability, and preliminary efficacy of the drug in late-stage solid tumor patients as a single agent, and determining the maximum tolerated dose and recommended Phase II dose. Currently, the study is being conducted simultaneously in China and the United States.

The 4th STING & TLR Targeted Therapy Summit brought together more than 100 industry-leading immune targeted therapy organizations from the large biopharmaceutical industry and academic institutions. The event provides a unique opportunity to present and share the latest development and progress in the field of STING and TLR agonist based therapeutics.

CanWell presented the preclinical research results of CAN1012, a small molecule TLR7 agonist in the form of an oral presentation at the 9th Immuno-oncology 360° (IO360°) conference.

The IO360° conference is a globally renowned annual conference for cancer immunotherapy, providing a collaboration opportunity for pharmaceutical/biotech companies, academia, and investors. The conference offers the platform where the latest progresses of cancer immunotherapy are shared and exchanged.

CanWell announced today that the preclinical results of its small molecule TLR7 agonist CAN1012 were presented at the 37th Annual Meeting of the Society for Immunotherapy of Tumors (SITC 2022, Boston).

Abstract ID: #1171

Poster title: CAN1012: A SELECTIVE AND POTENT TLR7 AGONIST WITH STRONG ANTITUMORAL PROPERTIES MEDIATED BY LOCALIZED INNATE IMMUNE ACTIVATION

Time: November 8-12, 2022. Boston US

CAN1012 is a slow-release selective TLR7 receptor agonist exclusively developed by CanWell with global intellectual property rights. Preclinical studies have shown that CAN1012 has high selectivity and activities with low toxicities.  It continuously stimulates the target immune cells in the tumor microenvironment, releasing a variety of cytokines/chemokines related to drug efficacy, thereby promoting the activation of anti-tumor immune cells and their infiltration into the tumor, transforming the “cold” tumor with a low immune response into a “hot” tumor with a strong immune response. When CAN1012 is used as a single agent in various preclinical tumor models, it has shown robust anti-tumor activities, while exhibiting extremely low systemic exposure. In addition, CAN1012 can be combined with a variety of tumor immune checkpoint inhibitors, targeted therapy drugs or chemotherapy to produce stronger anti-tumor activities.

CAN1012 is currently in clinical Ph I development  in China and the United States. In June 2021, it obtained IND approval from the US FDA and entered phase I clinical trial (NCT04987112) in the US. In July 2022, it received IND clearance from the Chinese CDE (JXHL2200119). A multi-center phase I clinical trial is currently ongoing in China.

CanWell Biotech Ltd. , a company specializing in the development of innovative immune-oncology drugs, announced today that the 1^st patient has been successfully dosed in its ongoing CAN1012 Ph1 clinical trial in China.

The CAN1012 Phase I clinical trial is an open-label, multicenter, dose-escalation, and dose-expansion study aimed at evaluating the safety, tolerability, and preliminary efficacy of the drug in late-stage solid tumor patients as a single agent, and determining the maximum tolerated dose and recommended Phase II dose. Currently, the study is being conducted simultaneously in China and the United States.

CAN1012 is a highly selective small-molecule TLR7 agonist developed by CanWell with global intellectual property rights. Preclinical studies have shown that it has high selectivity and potency, with low toxicities. It can exert sustained stimulation of the target cells in the tumor microenvironment, transforming “cold” tumors with low immune response into “hot” tumors with augmented immune response, playing a crucial bridging role in the innate and adaptive immune systems. In addition, it may be administered in combination with various drugs such as immunotherapy checkpoint inhibitors, as well as radiotherapy and chemotherapy, to produce highly synergistic effects.

Canwell announced today that its TLR7 agonist CAN1012 had obtained clinical trial approval from China’s Center for Drug Evaluation (CDE). The approval allows CanWell to conduct Phase I clinical trials targeting advanced solid tumors in China. Prior to this, CAN1012 had obtained Phase I clinical trial approval from the US Food and Drug Administration (FDA) and Phase I clinical trial in the US is currently ongoing.

The CAN1012 Phase I clinical trial is an open-label, multicenter, dose-escalation, and dose-expansion study aimed at evaluating the safety, tolerability, and preliminary efficacy of the drug in late-stage solid tumor patients as a single agent, and determining the maximum tolerated dose and recommended Phase II dose. Currently, the study is being conducted simultaneously in China and the United States.

CAN1012 is a highly selective small-molecule TLR7 agonist developed by CanWell with global intellectual property rights. Preclinical studies have shown that it has high selectivity and potency, with low toxicities. It can exert sustained stimulation of the target cells in the tumor microenvironment, transforming “cold” tumors with low immune response into “hot” tumors with augmented immune response, playing a crucial bridging role in the innate and adaptive immune systems. In addition, it may be administered in combination with various drugs such as immunotherapy checkpoint inhibitors, as well as radiotherapy and chemotherapy, to produce highly synergistic effects.